Journal of Cardiac Failure

Editor's Page: The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. @dranulala @robmentz onlinejcf.com/article/S1071-…

Final Call 🚨 Submissions close tomorrow for JCF’s Focus Issue on Innovations in Heart Transplantation. If your research offers new insight into transplantation techniques, outcomes, or care models, don’t miss the deadline 👉 April 10, 2026 #CallForPapers #HeartTransplantation

🔗 bit.ly/4rTor1T

The accompanying editorial calls for action🚨 Identify GDMT gaps early, initiate Rx in supportive settings, & build systems that allow safe, rapid optimization of HF Rx. The issue isn’t whether GDMT works, it’s whether systems will invest in delivering it. 🧵

New science🚨 Early initiation & uptitration of Sac/Val💊 vs ACEI/ARB in pts w/AHF led to ⬆️NT-proBNP reduction w/o AEs. Sac/Val💊 uptitration linked to: ⬇️kidney dysfunction ⬆️NYHA class. Results support timely Sac/Val initiation & thoughtful uptitration🚀 🧵

HFpEF: 🫁 ultrasound found pulmonary congestion more often than routine exam. More B-lines = worse symptoms, ⬆️ NPs & filling pressures—yet ~40% with highest B-lines had no crackles or ⬆️ NT-proBNP. LUS may help monitor congestion. 🔗 bit.ly/4rNOJTe

@robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

A potential new frontier for pulmonary hypertension therapy. Watch the conversation. 📍Filmed at #THT2026 🤝 In collaboration with @crfheart and @HFSA #PulmonaryHypertension #HeartFailure

📹 #THT2026 Hot Take Assessing & managing RV function remains one of our field's biggest challenges. With @RyanTedfordMD, we discussed: 🫀RV parameters to focus on with or without LVAD support ⚡️ Pulmonary artery denervation for PH associated w/left heart disease. 🧵

#HeartFailure #Cardiology @robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

🫀HF = one of the most dynamic fields in cardiology 📉 Yet fellowship numbers are down 💡 Mentorship, identity & training culture matter. 🎬 Filmed at #THT2026 📷 In collaboration with @CRF and @HFSA

📹 #THT2026 Hot Take Why are fewer trainees choosing Advanced HF/Transplant fellowships? @dranulala spoke with @ElenaDonaldMD (Columbia) about the trainee perspective: Watch the conversation.

@robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

This includes ultrasound use, PA catheter controversy, MCS selection, pharmacologic variation, and differences between AMI‑CS and HF‑CS—pointing to major opportunities for future investigation. Watch the discussion 📹

Drs. Carnicelli and @JasonKatzMD highlight key areas of international agreement and debate in diagnosing and managing HF‑related cardiogenic shock 🧵

@robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

📍Filmed at #THT2026 🤝 In collaboration with @crfheart and @HFSA #AIinMedicine #ClinicalTrials #HeartFailure

📹 #THT2026 Hot Take: AI is starting to reshape clinical trials. With Jon Cunningham, we discussed: Can AI based digital twins will replace the gold standard of randomizing patients in clinical trials? and how AI can aid in the efficient adjudication of clinical events 🤔

Check out the editorial: 1️⃣Lp(a) check identifies pts at ⬆️ risk of CV death or HF hosp🏥 (even accounting for NT-proBNP 🧪) 2️⃣Lp(a)+NT-proBNP ⚖️ = better risk stratification 3️⃣Lp(a)>50 mg/dL 💊📈 = consider aggressive lipid-lowering & closer follow-up 🔗 bit.ly/46ZIofV

🧬Lp(a) predicts new-onset HF but does it matter in chronic HF? In >1K HF pts, Lp(a) ≥30 mg/dL was linked to a 35% ⬆️ risk of CV death or HF hosp🏥, independent of NT-proBNP. The signal was stronger in ischemic HF. ⚠️High Lp(a)+NT-proBNP = highest-risk bit.ly/4cBlbEv